{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06390111",
            "orgStudyIdInfo": {
                "id": "000439"
            },
            "organization": {
                "fullName": "Ferring Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS \u00b1 High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.",
            "officialTitle": "A Phase 4, Multi-center, Open Label Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS \u00b1 High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.",
            "acronym": "ABLE-42",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-trial-to-evaluate-efficacy-of-reinduction-with-nadofaragene-firadenovec-in-subjects-with-cis-high-grade-ta-and-no-complete-response-to-first-nadofaragene-firadenovec-dose"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-07-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-07-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-19",
            "studyFirstSubmitQcDate": "2024-04-25",
            "studyFirstPostDateStruct": {
                "date": "2024-04-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Ferring Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "In this phase 4 trial (000439), subjects with NMIBC CIS (\u00b1 high-grade Ta/T1) who have not responded to their first dose of nadofaragene firadenovec (commercial ADSTILADRIN received before trial entry) will be offered reinduction when entering the trial."
        },
        "conditionsModule": {
            "conditions": [
                "Bladder Cancer",
                "Ta/T1",
                "CIS"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 25,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Nadofaragene Firadenovec",
                    "type": "EXPERIMENTAL",
                    "description": "Eligible subjects will receive nadofaragene firadenovec. This will be instilled quarterly in the bladder followed by quarterly disease assessments.",
                    "interventionNames": [
                        "Drug: nadofaragene firadenovec"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "nadofaragene firadenovec",
                    "description": "The investigational medicinal product dose, concentration, and assessments are aligned with nadofaragene firadenovec US prescribing information.",
                    "armGroupLabels": [
                        "Nadofaragene Firadenovec"
                    ],
                    "otherNames": [
                        "Adstiladrin"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Complete response (CR) achieved at month 3 after nadofaragene firadenovec retreatment",
                    "timeFrame": "at month 3"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maintenance of CR at months 6 after nadofaragene firadenovec retreatment",
                    "timeFrame": "at 6 months after nadofaragene firadenovec retreatment"
                },
                {
                    "measure": "Maintenance of CR at months 9 after nadofaragene firadenovec retreatment",
                    "timeFrame": "at 9 months after nadofaragene firadenovec retreatment"
                },
                {
                    "measure": "Maintenance of CR at months 12 after nadofaragene firadenovec retreatment",
                    "timeFrame": "at 12 months after nadofaragene firadenovec retreatment"
                },
                {
                    "measure": "Durability of CR at months 6 after nadofaragene firadenovec retreatment",
                    "description": "No evidence of CIS and/or high-grade Ta/T1",
                    "timeFrame": "at 6 months after nadofaragene firadenovec retreatment"
                },
                {
                    "measure": "Durability of CR at months 9 after nadofaragene firadenovec retreatment",
                    "description": "No evidence of CIS and/or high-grade Ta/T1",
                    "timeFrame": "at 9 months after nadofaragene firadenovec retreatment"
                },
                {
                    "measure": "Durability of CR at months 12 after nadofaragene firadenovec retreatment",
                    "description": "No evidence of CIS and/or high-grade Ta/T1",
                    "timeFrame": "at 12 months after nadofaragene firadenovec retreatment"
                },
                {
                    "measure": "Muscle-invasive progression of disease up to month 12 after nadofaragene firadenovec retreatment",
                    "timeFrame": "Up to12 months after nadofaragene firadenovec retreatment"
                },
                {
                    "measure": "Incidence of cystectomy",
                    "timeFrame": "Up to 12 months after nadofaragene firadenovec retreatment"
                },
                {
                    "measure": "Time to cystectomy",
                    "timeFrame": "Up to 12 months after nadofaragene firadenovec retreatment"
                },
                {
                    "measure": "Pathological staging at cystectomy",
                    "timeFrame": "Up to 12 months after nadofaragene firadenovec retreatment"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed, as documented, with CIS \u00b1 high-grade disease Ta/T1 and absence of progression after first dose of nadofaragene firadenovec within the last 5 months from instillation.\n* Diagnosed, as documented, with:\n\n  * Low risk of disease progression as assessed at the discretion of the investigator\n  * Previous Bacillus Calmette Guerin (BCG) therapy (BCG exposed) with no maximum limit to the amount of BCG administered\n\nExclusion Criteria:\n\n* Current or previous evidence of muscle-invasive (muscularis propria) or metastatic disease presented at the screening visit. Examples of increased risk of muscle-invasive include but are not limited to:\n\n  * Presence of lymphovascular invasion and / or micropapillary disease as shown in the histology of the biopsy sample\n  * Subjects with T1 disease accompanied by the presence of hydronephrosis secondary to the primary tumor\n* Current and prior systemic or local therapy for bladder cancer since first dose of nadofaragene firadenovec\n* Current or prior investigational treatment for BCG-unresponsive NMIBC or any other investigational drug (drug used in a clinical trial, i.e drug used in a Ferring sponsored non-interventional study does not apply) since first dose of nadofaragene firadenovec\n* Clinically significant and unexplained elevated liver or renal function tests\n* History of malignancy of other organ system within past 5 years, except treated basal cell carcinoma or squamous cell carcinoma of the skin and \u2264pT2 upper tract urothelial carcinoma at least 24 months after nephroureterectomy. Also subjects with genitourinary cancers other than urothelial cancer or prostate cancer that are under active surveillance are excluded",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "99 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Global Clinical Compliance",
                    "role": "CONTACT",
                    "phone": "1-888-FERRING (1-888-337-7464)",
                    "email": "DK0-Disclosure@ferring.com"
                },
                {
                    "name": "Global Clinical Compliance",
                    "role": "CONTACT",
                    "phone": "+1 862-286-5200 (outside US)",
                    "email": "DK0-Disclosure@ferring.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Global Clinical Compliance",
                    "affiliation": "Ferring Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Ferring Investigational Site",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30328",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Global Clinical Compliance",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001749",
                    "term": "Urinary Bladder Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014571",
                    "term": "Urologic Neoplasms"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000001745",
                    "term": "Urinary Bladder Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5030",
                    "name": "Urinary Bladder Neoplasms",
                    "asFound": "Bladder Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17320",
                    "name": "Urologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M5026",
                    "name": "Urinary Bladder Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}